Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

There are less than 72 hours left in this Mid-Year Campaign and our independent journalism needs your help today.
If you value our work, please support Common Dreams. This is our hour of need.

Join the small group of generous readers who donate, keeping Common Dreams free for millions of people each year. Without your help, we won’t survive.

For Immediate Release

Press Release

Sanders Investigates a $375,000 Price Spike on Old Drug

WASHINGTON -

In a letter sent Monday to the CEO of Catalyst Pharmaceuticals, Sen. Bernie Sanders (I-Vt.) demanded the company explain its decision to set the price of Firdapse, a drug used to treat a rare neuromuscular disease called Lambert-Eaton myasthenic syndrome (LEMS), at $375,000 per year.  

For two decades, patients have received the same drug – known as 3,4-DAP – for free from Jacobus Pharmaceutical under the Food and Drug Administration’s compassionate use program. Recently, Catalyst licensed the rights to the drug and received exclusive rights to market Firdapse for seven years under the FDA’s orphan drug designation. In December 2018, Catalyst announced to investors it would set the list price for Firdapse at $375,000 per year.

As a result, patients around the country are frightened as to whether or not they will be able to maintain access to a drug they depend upon to survive.

Last week, Sanders spoke via Skype with one of those patients, Rebecca Hovde of Wellman, Iowa, who told him about the incredible anxiety people with LEMS are living with as a result of Catalyst’s decision to increase the price. “I have friends saying that it’s too much. They know they can’t afford it. And they’re just going to go to bed when their 3,4 DAP runs out,” Hovde told Sanders. (Watch the full conversation here.)

In response to the concerns raised by Hovde and other patients, Sanders asked the CEO of Catalyst how many patients will suffer or die due to their decision to set such an outrageous price, calling that decision “not only a blatant fleecing of American taxpayers, but...also an immoral exploitation of patients who need this medication.” 

“By setting such a high price and forcing production and distribution of the older, inexpensive version to cease, you are threatening access that patients had to a cheap version of this product, and handing a completely unwarranted bill to American taxpayers,” Sanders wrote.

Sanders requested information on what Catalyst is charging patients, private insurers and government payers for the medication.

“The egregious price set by Catalyst cannot be allowed to stand.  Patients in America should not be allowed to suffer or die because of the greed of a drug company. If Catalyst does not substantially lower the price of this medication, Congress must act to ensure it is affordable for every patient,” Sanders said.

Read Sanders' letter to Catalyst here.

Naomi Klein: The US Is in the Midst of a 'Shock-and-Awe Judicial Coup'

"The rolling judicial coup coming from this court is by no means over," warned the author of "The Shock Doctrine."

Jake Johnson ·


Markey, Bowman Join Climate Coalition in Urging SCOTUS Expansion

"We cannot sit idly by," said Markey, "as extremists on the Supreme Court eviscerate the authorities that the government has had for decades to combat climate change and reduce pollution."

Brett Wilkins ·


Ocasio-Cortez Says US 'Witnessing a Judicial Coup in Process'

"It is our duty to check the Court's gross overreach of power in violating people's inalienable rights and seizing for itself the powers of Congress and the president."

Brett Wilkins ·


Critics Say Biden Drilling Bonanza 'Won't Lower Gas Prices' But 'Will Worsen Climate Crisis'

"President Biden's massive public lands giveaway in the face of utter climate catastrophe is just the latest sign that his climate commitments are mere rhetoric," said one campaigner.

Kenny Stancil ·


Grave Warnings as Supreme Court Agrees to Hear Case That Threatens 'Future of Voting Rights'

"Buckle up," implores one prominent legal scholar. "An extreme decision here could fundamentally alter the balance of power in setting election rules in the states and provide a path for great threats to elections."

Brett Wilkins ·

Common Dreams Logo